The Research Council of Norway continues to support next generation cryoimmunotherapy (CryoIT)
The Research Council of Norway has announced that 11 out of 87 received applications have been selected for funding in their programme called "High-quality and Reliable Diagnostics, Treatment and Rehabilitation (BEHANDLING)”. The project “Enhanced cryoimmunotherapy against urogenital cancers” by project leader Karl-Henning Kalland, CCBIO PI, was among the 11 selected projects and was one of two projects from Bergen that will receive funding. The application process has been very competitive, and it is considered a high-quality mark to be supported by the programme.
Important step forward
The allocation from BEHANDLING is a great stimulation and inspiration to the CryoIT project and teams and is essential for next stage CryoIT of both urological and gynecological cancers and towards robust production of potent therapeutic dendritic cells in Helse Bergen's planned Ex vivo facility.
Christian Beisland, Chief Department of Urology, Helse Bergen; Line Bjørge, Chief Department of Gynecology and CCBIO associated investigator; and Tor Hervig and Einar K. Kristoffersen, Professors and Chief of Department of Immunology and Transfusion Medicine, Helse Bergen, are PIs of the 3 different work packages of the application.
Also see earlier article on the CryiIT project.
Program targeted at areas with high disease burden
The BEHANDLING program supports clinical research activities to help to ensure that patients receive high-quality and reliable diagnostics, treatment and rehabilitation throughout their disease trajectory. Diseases that pose major societal challenges will comprise a key area of focus.
The thematic priorities of the programme are targeted towards areas in which there is a high disease burden, such as mental health disorders, musculoskeletal disorders, alcohol and drug addiction, cancer, cardiovascular disease and diseases affecting the brain and nervous system, as well as areas in which knowledge is lacking, such as chronic pain disorders and fatigue syndromes.